Literature DB >> 16393275

Review article: proton pump inhibitors and bacterial overgrowth.

C Williams1, K E L McColl.   

Abstract

Proton pump inhibitors are potent drugs producing profound suppression of gastric acid secretion. Consequently, they are highly effective at treating acid-related disorders. There have been concerns that the suppression of gastric acid will alter the bacterial flora of the upper gastrointestinal tract and lead to complications such as cancer, enteric or other infections and malabsorption. Studies have confirmed that proton pump inhibitors do alter the bacterial population but present evidence indicates that this only rarely leads to clinical disease. As with all drugs, proton pump inhibitors should only be used for disorders shown clearly to benefit from the therapy and where the benefits will outweigh the small risks associated with them. Further research to more fully quantify the risk associated with PPI therapy is required.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393275     DOI: 10.1111/j.1365-2036.2006.02707.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  70 in total

Review 1.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

2.  Reply to the letter by Kawada entitled ''Combined effect of proton-pump inhibitors and other drugs with regard to lower gastrointestinal tract bleeding with special reference to low-dose aspirin''.

Authors:  Naoyoshi Nagata; Takuro Shimbo
Journal:  J Gastroenterol       Date:  2015-11-03       Impact factor: 7.527

Review 3.  Inflammation, atrophy, and gastric cancer.

Authors:  James G Fox; Timothy C Wang
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 4.  Pharmacologic options in the management of upper gastrointestinal bleeding: focus on the elderly.

Authors:  Moe Htet Kyaw; Francis Ka Leung Chan
Journal:  Drugs Aging       Date:  2014-05       Impact factor: 3.923

5.  Does PPI therapy predispose to Clostridium difficile infection?

Authors:  Chaitanya Pant; Phillip Madonia; Anil Minocha
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

6.  Proton pump inhibitors in the management of GERD.

Authors:  Philip O Katz; Stacey Zavala
Journal:  J Gastrointest Surg       Date:  2009-09-23       Impact factor: 3.452

7.  Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS.

Authors:  David Law; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

Review 8.  Health benefits of probiotics: are mixtures more effective than single strains?

Authors:  C M C Chapman; G R Gibson; I Rowland
Journal:  Eur J Nutr       Date:  2011-01-13       Impact factor: 5.614

9.  Eosinophilic esophagitis: interactions with gastroesophageal reflux disease.

Authors:  Edaire Cheng; Rhonda F Souza; Stuart Jon Spechler
Journal:  Gastroenterol Clin North Am       Date:  2014-03-24       Impact factor: 3.806

10.  Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients.

Authors:  Richard A Schatz; Qing Zhang; Nilesh Lodhia; Jonathan Shuster; Phillip P Toskes; Baharak Moshiree
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.